10:57 AM
 | 
Jun 22, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK).

The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to treat community-acquired bacterial pneumonia (CABP)...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >